Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

Final Analysis of the Daliah Trial: A Randomized Phase III Trial of Interferon-α Versus Hydroxyurea in Patients with MPN

Blood (2023) 142 (Supplement 1): 746.

https://doi.org/10.1182/blood-2023-173127

Published: 2023

Journal Articles

Quality of Life and Symptom Burden of Patients with MPN during Treatment with Hydroxyurea or Pegylated Interferon-alpha2: Results from a Randomized Controlled Trial

Blood (2022) 140 (Supplement 1): 1794–1796.

https://doi.org/10.1182/blood-2022-156445

Published: 2022

Journal Articles

Robust Overall Survival and Sustained Efficacy Outcomes during Long Term Exposure to Momelotinib in JAK Inhibitor Naïve and Previously JAK Inhibitor Treated Intermediate/High Risk Myelofibrosis Patients

Srdan Verstovsek, MD PhD, Miklos Egyed, MD PhD, Ewa Lech-Marańda, MD PhD, Tomasz Sacha, MDPhD, Viviane Dubruille, MD, Stephen T. Oh, MD, Doroteya Todorieva-Todorova, MD, Francesco Passamonti, MD, Blanca Xicoy, MD, Björn Andréasson, MD PhD, Daniel El Fassi, MD, Claire Harrison, DM, FRCP, FRCPath, Donal P. McLornan, MRCP, PhD FRCPath, Mary Frances Frances McMullin, MDFRCPath,FRCP, Christof Scheid, MD, MArianne Tang Severinsen, MD PhD, Mark M Kowalski, MD PhD, Gregg Smith, PhD, Ruben Mesa, MD

Blood (2020) 136 (Supplement 1): 51–52.

https://doi.org/10.1182/blood-2020-135872

Published: 2020

Journal Articles

Therapeutic Cancer Vaccination Targeting Shared Tumor Associated Antigens in Combination with Azacitidine for High Risk Myelodysplastic Syndrome - a Phase I Clinical Trial

Staffan Holmberg-Thydén, MD, Inge Høgh Dufva, MDPhD, Anne Ortved Gang, MDPhD, Marie Fredslund Breinholt, MD, Lone Schejbel, PhD, Mette Klarskov Andersen, MD DMSc, Mohammad Kadivar, PhD, Inge Marie Svane, Prof,MDPhD, Kirsten Grønbæk, Prof,MDDMSc, Sine Reker Hadrup, Prof, Daniel El Fassi, MDPhD

Blood (2020) 136 (Supplement 1): 23–24.

https://doi.org/10.1182/blood-2020-142806

Published: 2020

Journal Articles

Genomic Profiling of a Phase III Clinical Trial of Interferon Versus Hydroxyurea in MPN Patients Reveals Mutation-Specific and Treatment-Specific Patterns of Response

Blood (2019) 134 (Supplement_1): 4202.

https://doi.org/10.1182/blood-2019-126164

Published: 2019

Journal Articles

Long-Term Efficacy and Safety of Recombinant Interferon Alpha-2 Vs. Hydroxyurea in Polycythemia Vera: Preliminary Results from the Three-Year Analysis of the Daliah Trial - a Randomized Controlled Phase III Clinical Trial

Blood (2018) 132 (Supplement 1): 580.

https://doi.org/10.1182/blood-2018-99-111255

Published: 2018

Journal Articles

No Development of Neutralizing Antibodies Against Recombinant Interferon-Alpha in Ph-Negative Myeloproliferative Neoplasms - a Prospective Study

Lukas Frans Ocias, Dennis Lund Hansen, Thomas Kielsgaard Kristensen, Karin de Stricker, Daniel El Fassi, MD PhD, Jesper Stentoft, Jørn Starklint, Mikael Frederiksen, Marianne Tang Severinsen, Ole Weis Bjerrum, MD DMSc, Peter Møller, Torben Mourits-Andersen, MD, Ulrik Malthe Overgaard, Hans Carl Hasselbalch, MD Professor, DMSc, Klaus Bendtzen, Thomas Stauffer Larsen, MD PhD

Blood (2015) 126 (23): 5177.

https://doi.org/10.1182/blood.V126.23.5177.5177

Published: 2015

Journal Articles

Safety and Efficacy of Combination Therapy of Interferon-Alpha2 + JAK1-2 Inhibitor in the Philadelphia-Negative Chronic Myeloproliferative Neoplasms. Preliminary Results from the Danish Combi-Trial - an Open Label, Single Arm, Non-Randomized Multicenter Phase II Study

Stine Ulrik Mikkelsen, MD, Lasse Kjær, MSc, PhD, Vibe Skov, MSc, PhD, Mads Emil Bjørn, MD PhDStudent, Christen Lykkegaard Andersen, MD PhD, Ole Weis Bjerrum, MD DMSc, Nana Brochmann, MD PhDStudent, Daniel El Fassi, MD PhD, Torben A Kruse, Professor, PhD, Thomas Stauffer Larsen, MD PhD, Torben Mourits-Andersen, MD, Claus Henrik Nielsen, MD Professor, DMSc, Niels Pallisgaard, MSc, Mads Thomassen, MSc, PhD, Hans Carl Hasselbalch, MD Professor, DMSc

Blood (2015) 126 (23): 824.

https://doi.org/10.1182/blood.V126.23.824.824

Published: 2015

NARROW

Final Analysis of the Daliah Trial: A Randomized Phase III Trial of Interferon-α Versus Hydroxyurea in Patients with MPN

Quality of Life and Symptom Burden of Patients with MPN during Treatment with Hydroxyurea or Pegylated Interferon-alpha2: Results from a Randomized Controlled Trial

Robust Overall Survival and Sustained Efficacy Outcomes during Long Term Exposure to Momelotinib in JAK Inhibitor Naïve and Previously JAK Inhibitor Treated Intermediate/High Risk Myelofibrosis Patients

Therapeutic Cancer Vaccination Targeting Shared Tumor Associated Antigens in Combination with Azacitidine for High Risk Myelodysplastic Syndrome - a Phase I Clinical Trial

Genomic Profiling of a Phase III Clinical Trial of Interferon Versus Hydroxyurea in MPN Patients Reveals Mutation-Specific and Treatment-Specific Patterns of Response

Long-Term Efficacy and Safety of Recombinant Interferon Alpha-2 Vs. Hydroxyurea in Polycythemia Vera: Preliminary Results from the Three-Year Analysis of the Daliah Trial - a Randomized Controlled Phase III Clinical Trial

No Development of Neutralizing Antibodies Against Recombinant Interferon-Alpha in Ph-Negative Myeloproliferative Neoplasms - a Prospective Study

Safety and Efficacy of Combination Therapy of Interferon-Alpha2 + JAK1-2 Inhibitor in the Philadelphia-Negative Chronic Myeloproliferative Neoplasms. Preliminary Results from the Danish Combi-Trial - an Open Label, Single Arm, Non-Randomized Multicenter Phase II Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only